Anthony J. Polverino

Director, BRAINSTORM CELL THERAPEUTICS INC.

Companies

BRAINSTORM CELL THERAPEUTICS INC.Board member Feb 5, 2018 to now¹
ZymeworksChief Scientific Officer Jan 2, 2019 to Jan 7, 2022²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Zymeworks ZYME36,407 shares³$930.6K at $25.56Jan 7, 2022
BRAINSTORM CELL THERAPEUTICS INC. BCLI25,730 shares⁴$19.9K at $0.78Jan 1, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

Jan 1, 2025Granted 24,000 shares of BRAINSTORM CELL THERAPEUTICS INC.⁴
Feb 1, 2022Granted 3,882 shares of BRAINSTORM CELL THERAPEUTICS INC.⁵
Jan 7, 2022Granted 74 shares at $13.94 of Zymeworks³
Dec 15, 2021Granted 2,000 shares of BRAINSTORM CELL THERAPEUTICS INC.⁶
Dec 10, 2021Granted 2,000 shares of BRAINSTORM CELL THERAPEUTICS INC.⁷
Dec 10, 2021Granted 2,216 shares of BRAINSTORM CELL THERAPEUTICS INC.⁷

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARBRAINSTORM CELL THERAPEUTICS INC., Board member
2
SEC EDGARZymeworks, Chief Scientific Officer
3
SEC EDGARZymeworks shares after the filing of Jan 7, 2022
4
SEC EDGARBRAINSTORM CELL THERAPEUTICS INC. shares after the filing of Jan 1, 2025
5
SEC EDGARForm 4 filed Feb 3, 2022
6
SEC EDGARForm 4 filed Dec 17, 2021
7
SEC EDGARForm 4 filed Dec 10, 2021